BusinessActinium Announces Proposed Public Offering of Common StockBy Nasdaq OMXSep 28, 2016, 8:10 PM UTC
BusinessNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023; Transparency Market ResearchBy Nasdaq OMXSep 27, 2016, 1:30 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessActinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60By Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessActinium Pharmaceuticals to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow TransplantBy Nasdaq OMXSep 26, 2016, 11:00 AM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessActinium Pharmaceuticals to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical TrialBy Nasdaq OMXSep 21, 2016, 12:01 PM UTC
BusinessActinium Pharmaceuticals to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical TrialBy Nasdaq OMXSep 21, 2016, 12:01 PM UTC
